ALDX · CIK 0001341235
What Aldeyra Therapeutics, Inc. told the SEC could break it.
Aldeyra's disclosures are those of a pre-revenue biotech whose value rests on a single bet. It has no approved products and won't earn product revenue until regulatory approval, and that hope concentrates in its lead candidate reproxalap (plus ADX-2191) — with its AbbVie collaboration still just an option AbbVie had not exercised as of late February 2026, leaving the deal and its milestone payments contingent on a favorable FDA decision. To fund development it depends on equity and debt financing, and it owns no manufacturing, relying entirely on third-party contract manufacturers for raw materials, drug substance, and finished product, with no contracts yet in place for commercial-scale supply.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Liquidity & debt
- pre-revenue; dependence on financing/partner paymentsmedium
Aldeyra has no approved products or product revenue and will not until regulatory approval; it depends on equity/debt financing and potential AbbVie option/milestone payments to fund development.
“We have no products approved for sale in the United States or elsewhere. We will not receive any revenue from sales of our product candidates that we develop until we obtain regulatory approval.”
SEC filing →As of 2026
Other disclosures
- single lead candidate (reproxalap) & unexercised AbbVie optionmedium
Aldeyra's value is concentrated in lead candidate reproxalap (and ADX-2191); the AbbVie collaboration is an option AbbVie had not exercised as of Feb 27, 2026, making the deal and revenue contingent on a favorable FDA decision.
“As of February 27, 2026, AbbVie has not exercised the AbbVie Option.”
SEC filing →As of 2026
Supplier concentration
- full reliance on third-party CMOs (no commercial-supply contracts)medium
Aldeyra owns no manufacturing and depends on third-party contract manufacturers for all raw materials, drug substance and finished product, and has no current contractual relationships for commercial-scale supply of its candidates.
“We currently depend on third-party contract manufacturers for all of our required raw materials, drug substance and finished drug product for our preclinical research and clinical trials. We have no immediate plans to purchase, erect, or otherwise create any manufacturing facilities to be owned by us for any of these purposes, and intend to continue to depend on third-party contract manufacturers for the foreseeable future.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“In the United States, we would share profits and losses with AbbVie from the commercialization of reproxalap according to a split of 60% for AbbVie and 40% for us. Outside of the United States, we would be eligible to receive tiered royalties on net sales of reproxalap.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch